18:31
Summary
Updated
18:25
17:52
Updated
16:46
15:40
Updated
15:20
The approval of a new protein-based Covid-19 vaccine by the European Medicines Agency (EMA) has led to hopes that it could play an important role in persuading millions of people in Germany who have refused jabs from existing vaccines to get protection against the disease this winter.
The EMA approved the two-dose Novavax vaccine on Monday afternoon. The German government’s vaccination advisory board is expected to follow suit and allow for its use soon, a move that would be welcomed by health experts who are bracing for a huge and imminent wave of infections caused by the new Omicron variant.
The first doses of Novavax are expected to be administered in Germany in the new year. The EU has secured 100m doses of Novavax and 60m doses of Valneva, with 4m Novavax doses immediately destined for Germany.
Across Europe, but in particular in Germany, experts are hoping that both vaccines will have the effect of persuading those who have so far turned down the offer of a vaccine to change their minds, at a time when raising immunity levels by vaccination is one of the key weapons against halting the virus’s spread.
So far, just over 70% of Germans are fully vaccinated. Unless this figure climbs to between 80 to 90%, the nation’s immunity will not be high enough to dampen the virus.
Read the full article here:
14:45
Updated
14:11
Updated
13:59
Summary
13:32
Queen Elizabeth won’t go to usual Sandringham family Christmas gathering
Updated
13:20
Updated
13:06
Updated
12:58
12:20
Updated
Discussion about this post